)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
Lantern Pharma (LTRN) investor relations material
Lantern Pharma Status Update summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Status Update summary20 Nov, 2025
Clinical trial results and safety profile
Phase I-A trial of LP-184 completed with favorable safety and tolerability, showing mostly manageable Grade 1 and 2 adverse events and no significant cumulative toxicity, even with long-term dosing.
Maximum tolerated dose established at dose level 11, with dose level 10 recommended for Phase II; dose-limiting toxicities were reversible and manageable.
Drug achieved therapeutic concentrations from dose level 7 upwards, supporting both monotherapy and combination regimens.
No significant hepatic or ocular toxicities observed, differentiating LP-184 from predecessors in its class.
Patients with advanced, heavily pretreated solid tumors, including those with DNA damage repair deficiencies, showed durable stable disease, with some on treatment for over a year.
Mechanism of action and biomarker strategy
LP-184 is a synthetic molecule inspired by illudin, designed for synthetic lethality in tumors with DNA damage repair deficiencies.
Efficacy is highly dependent on PTGR1 expression; tumors with high PTGR1 and DNA repair pathway mutations are most sensitive.
Developed an RT-qPCR assay for PTGR1 to enable precision medicine and tumor stratification.
LP-184 induces double-strand DNA breaks, with selectivity for tumor cells due to low PTGR1 in normal cells.
Combination with agents like Spironolactone and PARP inhibitors shows synergistic effects, expanding therapeutic potential.
Preclinical and clinical efficacy highlights
Demonstrated superior or comparable efficacy to PARP inhibitors in HR-deficient tumors, including triple-negative breast cancer and pancreatic cancer.
LP-184 effective in PARP inhibitor-resistant models and in combination regimens, showing complete tumor regression in preclinical studies.
High potency observed in pancreatic cancer models, with 20x-400x greater efficacy than standard agents.
Durable disease control observed in patients with DDR alterations, with some maintaining benefit for over a year.
High prevalence of PTGR1 expression in trial patients supports the biomarker-driven approach.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Lantern Pharma earnings date
Q4 202527 Mar, 2026
Next Lantern Pharma earnings date
Q4 202527 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Lantern Pharma Inc. is a clinical-stage biotechnology company focused on leveraging artificial intelligence and genomic data to develop precision oncology therapeutics. The company’s pipeline targets a range of cancers with the aim of enhancing treatment outcomes and reducing development risks. Lantern Pharma Inc. is headquartered in Dallas, Texas, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage